ABCL - AbCellera Biologics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Vancouver,
Canada
Type: Equity
ABCL price evolution
ABCL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $173.31 | $148.57 | $158.32 | |
| Short term investments | $522.04 | $574.45 | $627.26 | |
| Net receivables | $63.24 | $36.14 | $34.42 | $30.59 |
| Inventory | $0.74 | $1.11 | ||
| Total current assets | $742.88 | $771.55 | $813.95 | $871.99 |
| Long term investments | $76.06 | $71.59 | $65.94 | |
| Property, plant & equipment | $331.26 | $318.88 | $306.08 | $287.7 |
| Goodwill & intangible assets | $133.47 | $166.54 | $168.23 | |
| Total noncurrent assets | $640.93 | $649.15 | $616.11 | |
| Total investments | $598.11 | $646.04 | $693.2 | |
| Total assets | $1392.83 | $1412.48 | $1463.1 | $1488.09 |
| Current liabilities | ||||
| Accounts payable | $34.8 | $68.42 | $99.38 | $104.97 |
| Deferred revenue | $14.37 | $19.14 | $27.15 | |
| Short long term debt | ||||
| Total current liabilities | $79.57 | $70.38 | $104.88 | $119.01 |
| Long term debt | $66.45 | $68.08 | $71.22 | |
| Total noncurrent liabilities | $231.13 | $228.3 | $216.76 | |
| Total debt | $66.45 | $68.08 | $71.22 | |
| Total liabilities | $314.73 | $301.51 | $333.18 | $335.78 |
| Shareholders' equity | ||||
| Retained earnings | $151.14 | $202.25 | $239.18 | $279.79 |
| Other shareholder equity | -$1.23 | -$2.07 | -$1.82 | -$1.72 |
| Total shareholder equity | $1110.97 | $1129.91 | $1152.32 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $158.32 | $411.54 | $501.14 | $594.12 |
| Short term investments | $627.26 | $499.95 | $246.84 | |
| Net receivables | $30.59 | $603.36 | $160.58 | $213.24 |
| Inventory | $1.11 | $1.53 | $1.67 | |
| Total current assets | $871.99 | $1025.49 | $929.8 | $813.33 |
| Long term investments | $65.94 | $72.52 | $50.31 | $19.25 |
| Property, plant & equipment | $287.7 | $217.25 | $111.62 | $17.92 |
| Goodwill & intangible assets | $168.23 | $179.31 | $196.2 | $146.65 |
| Total noncurrent assets | $616.11 | $515.42 | $388.77 | $192.21 |
| Total investments | $693.2 | $572.47 | $297.15 | $19.25 |
| Total assets | $1488.09 | $1540.91 | $1318.57 | $1005.54 |
| Current liabilities | ||||
| Accounts payable | $104.97 | $14.83 | $90.41 | $56.3 |
| Deferred revenue | $27.15 | $41.13 | $68.29 | $32.48 |
| Short long term debt | $0.19 | |||
| Total current liabilities | $119.01 | $118.32 | $120.68 | $103.49 |
| Long term debt | $71.22 | $76.67 | $36.41 | $5.91 |
| Total noncurrent liabilities | $216.76 | $189.31 | $172.16 | $71.54 |
| Total debt | $71.22 | $76.67 | $36.41 | $6.1 |
| Total liabilities | $335.78 | $307.63 | $292.84 | $175.03 |
| Shareholders' equity | ||||
| Retained earnings | $279.79 | $426.19 | $267.67 | $114.2 |
| Other shareholder equity | -$1.72 | -$1.39 | $0.28 | |
| Total shareholder equity | $1152.32 | $1233.28 | $1025.73 | $830.51 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.51 | $7.32 | $9.95 | $9.18 |
| Cost of revenue | ||||
| Gross Profit | $7.32 | $9.95 | $9.18 | |
| Operating activities | ||||
| Research & development | $40.93 | $39.29 | $48.62 | |
| Selling, general & administrative | $23.33 | $20.72 | $19.07 | |
| Total operating expenses | $100.17 | $100.78 | $64.85 | $75.23 |
| Operating income | -$93.45 | -$54.89 | -$66.05 | |
| Income from continuing operations | ||||
| EBIT | -$48.19 | -$42.75 | -$48.6 | |
| Income tax expense | -$11.53 | -$11.26 | -$2.14 | -$1.45 |
| Interest expense | $9.6 | |||
| Net income | ||||
| Net income | -$51.11 | -$36.93 | -$40.61 | -$47.15 |
| Income (for common shares) | -$36.93 | -$40.61 | -$47.15 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $38.02 | $485.42 | $375.2 | $233.16 |
| Cost of revenue | ||||
| Gross Profit | $38.02 | $485.42 | $375.2 | $233.16 |
| Operating activities | ||||
| Research & development | $175.66 | $107.88 | $62.06 | $29.39 |
| Selling, general & administrative | $75.18 | $66.75 | $48.76 | $15.75 |
| Total operating expenses | $275.23 | $268.91 | $170.79 | $77.12 |
| Operating income | -$237.21 | $216.51 | $204.41 | $156.03 |
| Income from continuing operations | ||||
| EBIT | -$174.03 | $243.14 | $224.37 | $164.34 |
| Income tax expense | -$27.63 | $80.58 | $65.69 | $38.91 |
| Interest expense | $4.04 | $5.22 | $6.51 | |
| Net income | ||||
| Net income | -$146.4 | $158.52 | $153.46 | $118.92 |
| Income (for common shares) | -$146.4 | $158.52 | $153.46 | $118.92 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$36.93 | -$40.61 | -$47.15 | |
| Operating activities | ||||
| Depreciation | $38.04 | $6.77 | $9.11 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $17.78 | $17.41 | $16.45 | |
| Total cash flows from operations | -$29.97 | -$41.71 | -$19.61 | |
| Investing activities | ||||
| Capital expenditures | -$20.11 | -$24.14 | -$14.43 | |
| Investments | $59.63 | $46.88 | -$20.18 | |
| Total cash flows from investing | $85.71 | $52.1 | $29.91 | -$24.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.46 | $0.89 | ||
| Net borrowings | $2.37 | $2.12 | $3.95 | |
| Total cash flows from financing | $8.63 | $2.65 | $2.83 | $3.77 |
| Effect of exchange rate | -$0.46 | -$0.04 | -$0.78 | $1.07 |
| Change in cash and equivalents | -$6.68 | $24.74 | -$9.75 | -$39.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$146.4 | $158.52 | $153.46 | $118.92 |
| Operating activities | ||||
| Depreciation | $30.89 | $33.1 | $17.25 | $5.27 |
| Business acquisitions & disposals | -$11.46 | -$85.86 | ||
| Stock-based compensation | $64.18 | $49.48 | $30.65 | $8.4 |
| Total cash flows from operations | -$43.88 | $277.36 | $244.58 | $22.69 |
| Investing activities | ||||
| Capital expenditures | -$76.95 | -$70.66 | -$58.45 | -$9.67 |
| Investments | -$168.91 | -$296.4 | -$294.96 | -$19.25 |
| Total cash flows from investing | -$221.11 | -$352.63 | -$332.25 | -$119.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.62 | $523.84 | ||
| Net borrowings | $11.59 | $2.43 | -$0.95 | $85.15 |
| Total cash flows from financing | $10.36 | -$1.63 | -$3.89 | $683.65 |
| Effect of exchange rate | $0.59 | -$9.6 | -$1.43 | |
| Change in cash and equivalents | -$254.04 | -$86.49 | -$92.97 | $586.56 |
News
Fundamentals
| Market cap | $1.66B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 290.82M |
| Revenue | $32.96M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$175.80M |
| Revenue Q/Q | -1.39% |
| Revenue Y/Y | -34.59% |
| P/E ratio | -9.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 50.38 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.60 |
|---|---|
| ROA | -12.22% |
| ROE | N/A |
| Debt/Equity | 0.29 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.34 |
| Quick ratio | N/A |